| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net revenue | ||||||||||||||||
61,732 | 74,645 | 64,265 | 64,948 | 57,123 | 63,599 | 50,769 | 43,552 | 35,529 | 53,142 | 51,458 | 54,071 | 39,837 | - | - | - | - |
Cost of goods sold | ||||||||||||||||
18,793 | 20,391 | 19,131 | 19,446 | 16,980 | 17,510 | 19,477 | 17,300 | 14,521 | 16,422 | 16,087 | 15,406 | 13,305 | - | - | - | - |
Gross profit | ||||||||||||||||
42,939 | 54,254 | 45,134 | 45,502 | 40,143 | 46,089 | 31,292 | 26,252 | 21,008 | 36,720 | 35,371 | 38,665 | 26,532 | - | - | - | - |
Operating expenses: | ||||||||||||||||
Selling, general and administrative | ||||||||||||||||
52,613 | 52,368 | 49,475 | 48,957 | 48,893 | 47,478 | 38,583 | 37,735 | 38,165 | 36,387 | 35,662 | 33,716 | 27,952 | - | - | - | - |
Research and development | ||||||||||||||||
5,410 | 3,640 | 3,924 | 3,864 | 3,371 | 3,091 | 2,779 | 2,048 | 2,824 | 2,735 | 2,325 | 2,454 | 1,551 | - | - | - | - |
Write-off of deferred offering costs | ||||||||||||||||
- | - | - | 0 | - | - | - | 3,494 | - | - | - | - | - | - | - | - | - |
Total operating expenses | ||||||||||||||||
58,023 | 56,008 | 53,399 | 52,821 | 52,264 | 50,569 | 41,362 | 43,277 | 40,989 | - | - | - | - | 178 | 14 | 0 | 15 |
Loss from operations | ||||||||||||||||
-15,084 | -1,754 | -8,265 | -7,319 | -12,121 | -4,480 | -10,070 | -17,025 | -19,981 | -2,402 | -2,616 | 2,495 | -2,971 | -1,298 | -14 | - | - |
Other expense, net: | ||||||||||||||||
Interest expense, net | ||||||||||||||||
2,510 | 2,604 | 2,427 | 2,187 | 1,778 | 2,663 | 2,940 | 2,781 | 2,429 | 2,283 | 2,233 | 2,031 | 1,592 | - | - | - | - |
Interest income | ||||||||||||||||
- | - | - | - | - | 5 | - | - | 19 | 28 | 28 | 35 | 38 | - | - | - | - |
Change in fair value of warrants | ||||||||||||||||
- | - | - | 0 | - | 170 | 50 | 175 | 74 | 53 | 534 | 505 | -55 | - | - | - | - |
Loss on the extinguishment of debt | ||||||||||||||||
- | 0 | 0 | 0 | -1,862 | -2,095 | - | - | - | - | - | - | - | - | - | - | - |
Gain on settlement of deferred acquisition consideration | ||||||||||||||||
1,295 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Other income, net | ||||||||||||||||
21 | 2 | -1 | -120 | 132 | 150 | 9 | -2 | 5 | 49 | -1 | -119 | 62 | - | - | - | - |
Total other expense, net | ||||||||||||||||
-1,194 | -2,602 | -2,428 | -2,307 | -3,508 | -4,773 | -2,981 | -2,958 | -2,479 | -2,259 | -2,740 | -2,620 | -1,437 | - | - | - | - |
Net loss before income taxes | ||||||||||||||||
-16,278 | -4,356 | -10,693 | -9,626 | -15,629 | -9,253 | -13,051 | -19,983 | -22,460 | -4,661 | -5,356 | -125 | -4,408 | - | - | - | - |
Income tax expense | ||||||||||||||||
35 | 42 | 48 | 23 | 37 | 2 | 27 | 27 | 28 | -233 | 47 | -156 | -6,683 | - | - | - | - |
Net loss | ||||||||||||||||
- | - | - | -9,649 | - | -9,255 | - | -20,010 | -22,488 | -4,428 | -5,403 | -242 | 1,685 | - | - | - | - |
Net income attributable to non-controlling interest in affiliates | ||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 273 | 590 | - | - | - | - |
Net loss | ||||||||||||||||
-16,313 | - | -10,741 | - | -15,666 | -9,255 | -13,078 | - | - | -4,428 | -5,403 | 31 | 2,275 | -178 | -14 | -0 | -15 |
Non-cash deemed dividend to warrant holders | ||||||||||||||||
- | - | -645 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net loss attributed to Organogenesis Holdings Inc. common shareholders | ||||||||||||||||
- | - | -11,386 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net loss per share—basic and diluted | ||||||||||||||||
-0.16 | -0.04 | -0.12 | -0.11 | -0.17 | -0.12 | -0.19 | -0.30 | -0.35 | - | - | - | - | -0.02 | 0.00 | 0.00 | 0.00 |
Weighted-average common shares outstanding—basic and diluted | ||||||||||||||||
104,486 | 97,833 | 92,276 | 90,647 | 90,604 | 76,952 | 69,496 | 66,361 | 64,320 | - | - | - | - | 9,184 | 7,500 | 7,500 | 7,500 |